Oral Presentations

Oral Presentations

OP0231 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB WAS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED AND QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-C

Oral Presentations

Désirée van der Heijde, Lianne S. Gensler, Atul Deodhar, Xenofon Baraliakos, Denis Poddubnyy, Mary Katherine Farmer, Dominique Baeten, Jason Coarse, Marga Oortgiesen, Maxime Dougados

OP0031 ARE THE MODIFIED NEW YORK AND ASAS AXIAL SPONDYLOARTHRITIS CRITERIA INTERCHANGEABLE IN THE CLASSIFICATION OF SPONDYLOARTHRITIS PATIENTS WITH RADIOGRAPHIC SACROILIITIS: COMPARISON IN 8 COHORTS?.

Oral Presentations

Anne Boel, Anna Moltó, Désirée van der Heijde, Adrian Ciurea, Maxime Dougados, Lianne S. Gensler, Maria Jose Santos, Eugenio de Miguel, Denis Poddubnyy, Martin Rudwaleit, Astrid van Tubergen, Floris A. van Gaalen, Sofia Ramiro

Search form

You are here

OP0231 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB WAS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED AND QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-C

OP0031 ARE THE MODIFIED NEW YORK AND ASAS AXIAL SPONDYLOARTHRITIS CRITERIA INTERCHANGEABLE IN THE CLASSIFICATION OF SPONDYLOARTHRITIS PATIENTS WITH RADIOGRAPHIC SACROILIITIS: COMPARISON IN 8 COHORTS?.